Clinical trials: Depressed Mood
Depressive Disorder
A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
The primary objective is to evaluate the safety and tolerability of abrupt discontinuation of saredutant over 1 week in outpatients with depression who completed 8 weeks of treatment with saredutant 100 mg once daily.
- Trial name
- NCT00429260
- Testing
- Saredutant
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Sanofi
Postpartum Depression, Postnatal Depression
Phase 2 Clinical Trial of GH001 in Postpartum Depression
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 female participants with clinically diagnosed postpartum depression (PPD) will be included in this study.
- Trial name
- NCT05804708
- Testing
- GH001
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 10 people
- Sponsor
- GH Research Ireland Limited
Depressive Disorder, Depressive Symptoms
AI Mental Health Tool vs. Psychoeducation Control
The goal of this clinical trial is to learn if Ash, an AI chat tool for mental health, works better than static psychoedcuation in reducing mental health symptoms.
- Trial name
- NCT07841483
- Testing
- Ash, Brief Therapist-Delivered Telehealth
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Slingshot AI
Depressive Disorder, Major, Anxiety Disorders
Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)
Approximately 20 sites in Korea including the Catholic University of Korea, Yeouido St. Mary's Hospital. Patients with Depressive disorders taking a selective serotonin reuptake inhibitor (SSRI) antidepressant or Serotonin and…
- Trial name
- BASIS (NCT04770454)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Major Depressive Disorder
GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects
To evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of GW117 ODT in healthy volunteers
- Trial name
- NCT06964711
- Testing
- GW117 ODT
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co.,Ltd.
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
- Trial name
- NCT01573598
- Testing
- Vilazodone
- Where
- 75 sites in United States, Bulgaria and 6 more
- Volunteers
- 1,219 people
- Sponsor
- Forest Laboratories
Bipolar Depression, Major Depressive Disorder
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or…
- Trial name
- NCT04285515
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 488 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Postpartum Depression
A Phase II Study of HS-10353 in Participants With Postpartum Depression
The primary purpose of this study is to determine if treatment with HS-10353 reduces depressive symptoms in participants with postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the 17-item…
- Trial name
- NCT05937867
- Testing
- HS-10353 Capsules 30 mg, Oral, QN for 14 days, HS-10353 Capsules 50 mg, Oral, QN for 14 days
- Volunteers
- 96 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Depression, Depressive Disorder
Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
The purpose of this study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00366652
- Testing
- desvenlafaxine SR, desipramine, duloxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder
A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
This is a 6-week, randomised, multicenter, double-blind, placebo controlled, fixed dose parallel group study to assess the efficacy and safety of orvepitant (30 and 60 mg/day) versus placebo in subjects with a diagnosis of a…
- Trial name
- Orvepitant MDD (NCT00880048)
- Testing
- orvepitant
- Where
- 32 sites in United States, Canada
- Volunteers
- 343 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Depression
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Polaris (NCT01360632)
- Testing
- OPC-34712 + ADT
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 1,539 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without…
- Trial name
- NCT07065240
- Testing
- SPT-300
- Where
- 61 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Seaport Therapeutics
Major Depressive Disorder (MDD)
Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
This is a study to obtain clinical experience of 323U66 SR for elderly patients with depression in repeat-dose of 323U66 SR up to 300mg/day, and to conduct exploratory investigation on safety, efficacy and pharmacokinetics…
- Trial name
- NCT00330616
- Testing
- 323U66 SR
- Where
- 9 sites in Japan
- Volunteers
- 35 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor [SSRI] or serotonin-norepinephrine reuptake inhibitor…
- Trial name
- VENTURA-5 (NCT06635135)
- Testing
- Aticaprant
- Where
- 95 sites in United States, Argentina and 11 more
- Volunteers
- 47 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01179516
- Testing
- Vortioxetine
- Where
- 61 sites in United States
- Volunteers
- 469 people
- Sponsor
- Takeda
Major Depressive Disorder, Idiopathic Parkinson Disease
Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
This study aims to assess the tolerability of duloxetine, 60mg once daily, in open label fashion, in depressed patients with Parkinson's disease during 12 weeks treatment.
- Trial name
- NCT00437125
- Testing
- Duloxetine hydrochloride
- Where
- 13 sites in Italy
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371734
- Testing
- Desvenlafaxine Succinate Sustained-Release
- Where
- 42 sites in United States, Chile and 1 more
- Volunteers
- 363 people
- Sponsor
- Pfizer
Treatment Resistant Depression
A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.
The primary objective of this study is to assess short, mid and long-term clinical outcomes in patients with difficult to treat depression (such as patients with treatment resistant depression) treated with Vagus Nerve…
- Trial name
- RESTORE-LIFE (NCT03320304)
- Testing
- Vagal Nerve Simulation (VNS) Therapy
- Where
- 18 sites in Austria, Belgium and 2 more
- Volunteers
- 500 people
- Sponsor
- LivaNova
Major Depressive Disorder (MDD)
Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)
The primary objective of this Phase IIa trial is to determine the effective dose and treatment period for an upcoming RX-10100 Phase IIb trial in subjects with major depression disorder (MDD).
- Trial name
- NCT00839176
- Testing
- RX-10100
- Where
- 3 sites in United States
- Volunteers
- 118 people
- Sponsor
- Rexahn Pharmaceuticals, Inc.
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- DIAMOND (NCT00321490)
- Testing
- Quetiapine fumarate, Duloxetine
- Where
- 34 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca